Floatz logo

Yttrium-90

Localized Non-Resectable Adult Liver Carcinoma

Vanderbilt-Ingram Cancer CenterradiopharmaceuticalDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Localized Non-Resectable Adult Liver Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Roswell Park Cancer Institute
Phase 3BBB
Irinotecan
University of Chicago
Phase 2BB
Inno-206
Case Comprehensive Cancer Center
Phase 3BB
Eloxatin
Case Comprehensive Cancer Center
Phase 2BB
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Yttrium-90 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Liver Cancer (Locally Advanced or Metastatic)Dormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →